screening of hypoglycemic agent

18
Amandeep Dhillon M-Pharm 2 nd Sem

Transcript of screening of hypoglycemic agent

Page 1: screening of hypoglycemic agent

Amandeep Dhillon

M-Pharm 2nd Sem

Page 2: screening of hypoglycemic agent

Pathogenesis of Type 1 & 2 Diabetes mellitus.

Diabetes mellitus is a chronic metabolic disorder characterised by a high blood glucose concentration Hyperglycemia due to insulin deficiency and/or insulin resistance.

Hyperglycemia occurs because of uncontrolled hepatic glucose output & reduced uptake of glucose by skeletal muscles with reduced glycogen synthesis.

Hypoglycemic effects causes “Blood sugar lowering” effects (Assay of insulin & insulin like activity).

Page 3: screening of hypoglycemic agent

Cataract Formation

Diabetic patients are known to have a higher incidence of cataract formation. Which produce changes in the transparency or the refractory index of the lens.

Aldose reductase catalyst the reduction of aldoses like “Glucose & Galactose” to corresponding polyols.

Aldose reductase inhibitors have been shown to prevent sugar induced cataract fomation.

Page 4: screening of hypoglycemic agent

Pathogenesis

GLUT Glucose transporter IAPP Islet amyloid poly-peptide

Page 5: screening of hypoglycemic agent

ClassificationA. Enhance Insulin secretion

Sulfonylureas (KATP channel blockers)

1st Gen:- Tolbutamide

2nd Gen:-Glimepiride

B. Overcome Insulin resistance

Biguanide (AMPK Activator)

Thiazolidinediones (PPAR Activator)

C. Miscellaneous anti-diabetic drugs

α- glucosidase inhibitors Bromocriptin, Pramlintide

Page 6: screening of hypoglycemic agent

In-Vivo Models

1. Streptozotocin induced DM

2. Blood sugar lowering effects in rabbits/mice.

3. Cataract formation in streptozotocin Diabetic rats.

4. Galactose induced cataract in rats.

5. Naphthalene induced cataract in rats.

6. Hypoglycemic seizures in mice.

7. Assay of glucose transport.

Page 7: screening of hypoglycemic agent

In-Vitro Models1. Assays of insulin & of insulin like activity

2. Isolated organs, cell & membranes

3. Insulin receptor Binding assay

4. Assays of other glucose regulating peptide hormones

5. Inhibition of polysaccharide degrading enzyme

6. Effect on secondary diabetes symptoms

7. Glucose uptake by the isolated diaphragm from mice & rats

8. Insulin receptor binding assays

9. Isolated pancreas of rat

10. Rat diaphragm test.

Page 8: screening of hypoglycemic agent

Streptozotocin induced DMStreptozotocin [60 mg/kg body weight] is prepared in citrated buffer [ph 4.5]

Albino rats of either sex weighing 150-200 g are injected i.p with above solution.

Animals showing fasting blood glucose levels > 140mg/dl after 48 hours ofstreptozotocin administration are considered diabetic.

After six weeks of treatment blood samples are collected from 6 hour fastinganimal

Serum is separated by centrifuge (3000 rpm) under cooling (2-4 °C) for tenminutes

Serum glucose level is estimated by glucose- peroxidase method [GOD-PODkit] using autoanalyser

Page 9: screening of hypoglycemic agent

Broad spectrum anti biotic – 200 mg/kg i.p.

MOA

β cell damage by free radical injury

Fragmentation of DNA

Nitric oxide generation

Induces diabetes in all species

Advantages

Greater selectivity towards beta cells

Low mortality

Longer and irreversible diabetes

Guinea pigs and rabbits are resistant

Page 10: screening of hypoglycemic agent

Insulin antibody induced diabetesPrinciple: - A transient diabetic syndrome can be induced by injecting guinea pigs with anti insulin serum.

Preparation of antibody

Bovine insulin, dissolved in acidified water [ph 3.0] at a doseof 1mg /ml

Anti insulin sera is collected after two weeks of antigenic challenge

Injected into guinea pigs

Page 11: screening of hypoglycemic agent

ProcedureAdult albino rats are injectedwith 0.25-1.0 ml of guinea piganti- insulin serum.

increase of blood glucose level up to 300mg/ dl.

The drug sample to bescreened is given andblood glucose level isanalyzed to determinethe activity.

Page 12: screening of hypoglycemic agent

Blood sugar lowering effecs in rabbits/mice.PURPOSE & RATIONALE :- A biological assay of

insulin preparations in comparison with a stable standard using the blood sugar lowering effects in rabbits.

EVALUATION :-The result of the assay are calculated by standard methods.

Rabbits 150mg/kg

Page 13: screening of hypoglycemic agent

Procedure

Rabbits 3-4.5kg div into groups of 4-5

• Insulin and insulin like compound-

• Food stopped a day earlier

• Hypoglycemic agents-diet till experiment

Test drug –orally 1ml/kg in0.4%starch suspension

• Control receives only the vehicle

• Different doses are tried on other groups

Blood is withdrawn before &1,2,3,4,5,24,48 and 72 hr

• Blood glucose is determined

• Blood sugar values are plotted against time

Page 14: screening of hypoglycemic agent

RAT MODEL Male Wistar rats -250 gms

Divided into 4 groups of 7 each

Test dose is given as per dose in starch suspension

Blood is drawn from the tip of the tail at 1,2,3,5,24 hours

Page 15: screening of hypoglycemic agent

IN VITRO METHODS ON ISOLATED ORGANS AND CELLS PRINCIPLE:- To study the effect of the drug on

insulin, glucagon & somatostatin secretion without interference from other organs.

INSULIN ASSAY:-

Four groups of six rabbits weighing at least 1.8 kg

Page 16: screening of hypoglycemic agent

Two standard solutions of insulin containing one unit and two units

respectively

Two dilutions of sample whose potency is being examined are prepared

After one hour and 2.5 h of each injection, a suitable blood sample is taken from the ear vein of each rabbit.

blood sugar determined by glucose oxidase method

Page 17: screening of hypoglycemic agent

Summary

Page 18: screening of hypoglycemic agent